Skip to main content
OpenTrials
Completed

NCT Number: NCT01768910

Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction

The purpose of this study is to provide profound insight into the supraspinal neuronal mechanisms and networks responsible for lower urinary tract (LUT) control and to verify, amend or adjust neuronal circuitry models established from findings in healthy subjects in the context of neurogenic and non-neurogenic LUT dysfunction.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neurogenic Lower Urinary Tract Dysfunction Autoimmune Diseases Autoimmune Diseases of the Nervous System Central Nervous System Diseases Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Immune System Diseases Lower Urinary Tract Symptoms Male Urogenital Diseases Multiple Sclerosis Nervous System Diseases Overactive Bladder Pathological Conditions, Signs and Symptoms Signs and Symptoms Spinal Cord Diseases Spinal Cord Injuries Spinal Cord Injury Trauma, Nervous System Urinary Bladder Diseases Urinary Bladder, Overactive Urogenital Diseases Urologic Diseases Urological Manifestations Wounds and Injuries

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Neuro-Urology, Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, Zurich, Switzerland

Loading trial locations.

About this study

The subject recruitment will be performed within the Neuro-Urology outpatient clinic at the Balgrist University Hospital and in collaboration with the Departments of Neurology, Urology and Gynecology at the University Hospital Zürich.

The following subject groups will be recruited: 1) healthy controls (n=22), Non-neurogenic overactive bladder (NNOAB) patients (n=20), multiple sclerosis (MS) patients with OAB (n=15), MS patients without OAB (n=15), spinal cord injury (SCI) patients with neurogenic detrusor overactivity (n=24).

After inclusion, all subjects and patients will undergo one to two functional magnetic resonance imaging (fMRI) sessions. NNOAB patients might undergo an additional fMRI session after receiving overactive bladder (OAB) treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A). Spinal cord injury (SCI) patients with neurogenic detrusor overactivity will undergo an additional fMRI session 5-7 weeks after intradetrusor injections of botulinum toxin type A.

High-resolution anatomical images and functional blood-oxygen-level-dependent (BOLD)-signal sensitive images will be acquired. In addition to the fMRI, diffusion tensor imaging (DTI) sequences will be recorded after the anatomical scans to provide information about the structural supraspinal connectivity.

Study endpoints are changes of the BOLD signal in regard to location and intensity, structural and functional connectivity (FC) between previously described supraspinal centers involved in LUT control, and statistical differences of changes in BOLD signals, structural and functional connectivity between patients and healthy controls.

All acquired fMRI data will be transferred to an off-line workstation running BrainVoyager QX or Statistical Parametric Mapping (SPM) Version 8. The functional data will be pre-processed for motion correction, spatial smoothing, linear trend removal, and temporal high-pass filtering. With both programs statistical analysis and graphical presentation of the results can be performed.

The DTI records will be evaluated with SPM8, BrainVoyager QX or other programs like Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL) and DTI-Studio. To estimate FC we will use SPM8 or the brain connectivity toolbox. Both softwares allow the estimation of rest- and task-related connectivity on single subject and group level with corrected statistical threshold.

Overall, 96 subjects for the main study are estimated to be sufficient to demonstrate significant differences between groups.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy controls

  • Right handed
  • MR suitability
  • Written informed consent
  • unimpaired LUT function

MS patients with OAB

  • Right handed
  • MR suitability
  • Written informed consent
  • diagnosis of MS according to the McDonald criteria
  • Expanded Disability Status Scale (EDSS) ≤ 6
  • OAB symptoms since > 6 months
  • ≥ 3 episodes of urinary urgency
  • frequency > 8/24h
  • with or without detrusor overactivity

MS patients without OAB

  • Right handed
  • MR suitability
  • Written informed consent
  • diagnosis of MS according to the McDonald criteria
  • Expanded Disability Status Scale (EDSS) ≤ 6

Patients with NNOAB

  • Right handed
  • MR suitability
  • Written informed consent
  • idiopathic OAB symptoms since > 6 months
  • ≥ 3 episodes of urinary urgency
  • frequency > 8/24h
  • refractory to antimuscarinic treatment for ≥ 1 month
  • indication for intradetrusor injections of Botulinumtoxin Type A
  • willingness and ability to perform self-catheterization

SCI patients with neurogenic detrusor overactivity

  • Right handed
  • MR suitability
  • Written informed consent
  • neurogenic detrusor overactivity due to SCI
  • indication for intradetrusor injections of botulinum toxin type A

Exclusion criteria

Healthy controls

  • impaired LUT function
  • pregnancy or breast feeding
  • no informed consent
  • any craniocerebral injury or surgery
  • any permanent ferromagnetic implant
  • any previous surgery of the LUT or genitalia
  • any anatomical anomaly of the LUT or genitalia
  • any LUT malignancy
  • postvoid residual urine volume (PVR) > 150ml
  • current urinary tract infection
  • any LUT symptoms
  • ≥ 3 episodes of urinary urgency
  • frequency > 8/24h

MS patients with OAB

  • pregnancy or breast feeding
  • any permanent ferromagnetic implant
  • any neurological or psychological disease despite MS
  • any craniocerebral injury or surgery
  • any previous surgery of the LUT or genitalia
  • any anatomical anomaly or malignancy of the LUT or genitalia
  • any metabolic disease
  • PVR > 150ml
  • any concomitant treatment for the LUT (e.g. neuromodulation)
  • Stress urinary incontinence
  • any condition other than MS that might explain OAB symptoms
  • current urinary tract infection
  • indwelling catheters or the necessity to perform self-catheterization

MS patients without OAB

  • pregnancy or breast feeding
  • any permanent ferromagnetic implant
  • any neurological or psychological disease despite MS
  • any craniocerebral injury or surgery
  • any previous surgery of the LUT or genitalia
  • any anatomical anomaly or malignancy of the LUT or genitalia
  • any metabolic disease
  • PVR > 150ml
  • any concomitant treatment for the LUT (e.g. neuromodulation)
  • Stress urinary incontinence
  • any LUT symptoms
  • ≥ 3 episodes of urinary urgency
  • frequency > 8/24h
  • indwelling catheters or the necessity to perform self-catheterization
  • detrusor overactivity
  • current urinary tract infection

Patients with NNOAB

  • pregnancy or planned within next 8 months, breast feeding
  • any permanent ferromagnetic implant
  • any neurological, psychological, metabolic or cardiovascular disease
  • any craniocerebral injury or surgery
  • any previous surgery of the LUT or genitalia within the last year or that is related to the OAB symptoms
  • any anatomical anomaly or malignancy of the LUT or genitalia
  • PVR > 150ml
  • Stress urinary incontinence
  • indwelling catheters or the necessity to perform self-catheterization
  • any concomitant treatment for the LUT (e.g. neuromodulation)
  • current urinary tract infection

SCI patients with neurogenic detrusor overactivity

  • pregnancy or breast feeding
  • any permanent ferromagnetic implant
  • any neurological or psychological disease despite SCI
  • any craniocerebral injury or surgery
  • any previous surgery of LUT of genitalia
  • any anatomical anomaly or malignancy of the LUT or genitalia
  • any metabolic disease
  • any concomitant treatment for the LUT (e.g. neuromodulation)
  • current urinary tract infection

Treatment and study plan

fMRI

Other

2 measurements using functional magnetic resonance imaging in a 3T scanner

bladder filling

Other

Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.

bladder cooling

Other

Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.

additional post-treatment fMRI scan

Other

Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.

Primary outcomes

  1. Bold signal

    Time frame: baseline and 4 weeks

    During fMRI measurements the changes of BOLD signal intensity in respect to certain supraspinal areas (e.g. pons, insula, anterior cingulate cortex, thalamus, supplementary motor area, prefrontal cortex) will be evaluated.

    Variables are age, bladder volume, urgency and attention.

  2. Structural and functional connectivity

    Time frame: baseline and after potential OAB treatment

    Acquired data from the above mentioned measurements will be used to analyze structural and functional connectivity between supraspinal areas involved in the LUT control, especially between prefrontal, thalamus, insula, and anterior cingulate cortex.

    Variables are age, bladder volume, urgency and attention. Correlations of neuronal activity from the fMRI-data will be estimated using SPM8, brain connectivity tool box.

Secondary outcomes

  1. Side effects

    Time frame: 3 years

    Pain, Lower urinary tract infection

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Collaborators

  • Balgrist University Hospital
  • Swiss National Science Foundation

Registry information

Official study title

The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques

Important dates

Study start
2011
Primary completion
2015
Study completion
2018
First posted
Jan 16, 2013
Registry last updated
Mar 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.